// App-Quantinova.ai

1318 : Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial

Researchers

Presenter

  • Constantine S. Tam

Principal Investigators

  • Ian W. Flinn

  • Alessandra Tedeschi

  • Emmanuelle Ferrant

  • Jennifer R. Brown

  • Tadeusz Robak

  • Paolo Ghia

  • Sowmya B. Kuwahara

  • Jason C. Paik

  • Lei Hua

  • Aileen Cohen

  • Jane Huang

  • Peter Hillmen

Medical Centers

  • St Vincent's Hospital, Fitzroy, Australia

  • Royal Melbourne Hospital, Parkville, Australia

  • University of Melbourne, Melbourne, Australia

  • Peter MacCallum Cancer Centre, Parkville, Australia.

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • Grande Ospedale Metropolitano Niguarda, Milan, Italy

  • Centre Hospitalier Lyon-Sud, University Claude Bernard Lyon 1, Pierre-Bénite, France

  • Dana-Farber Cancer Institute, Boston, MA

  • Medical University of Lodz, Lodz, Poland

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc.,San Mateo, CA,Vereinigte Staaten

  • St. James's University Hospital, Leeds, United Kingdom

Locations

  • Australia

  • United States

  • Italy

  • France

  • Poland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Lymphomas

Biomarkers

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • Venetoclax

  • BGB-3111

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Multinational

  • Multicenteric

  • Cohort

Phase

  • III

Study Id's

  • NCT03336333

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved